Shattuck Labs (NASDAQ:STTK) Coverage Initiated by Analysts at Needham & Company LLC

Needham & Company LLC assumed coverage on shares of Shattuck Labs (NASDAQ:STTK) in a research note issued to investors on Friday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $25.00 price target on the stock.

Several other analysts have also issued reports on STTK. Piper Sandler initiated coverage on shares of Shattuck Labs in a research report on Wednesday, January 28th. They set an “overweight” rating and a $15.00 target price for the company. Wedbush increased their price target on shares of Shattuck Labs from $4.00 to $8.00 and gave the stock an “outperform” rating in a research report on Friday. HC Wainwright upgraded shares of Shattuck Labs from a “neutral” rating to a “buy” rating and set a $6.00 price target on the stock in a research note on Monday, December 1st. Citigroup boosted their price objective on shares of Shattuck Labs from $2.00 to $4.00 and gave the company a “neutral” rating in a research report on Tuesday, January 6th. Finally, TD Cowen restated a “buy” rating on shares of Shattuck Labs in a research note on Friday. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $10.00.

Shattuck Labs Stock Up 17.5%

Shares of STTK opened at $5.99 on Friday. The stock has a market cap of $379.05 million, a P/E ratio of -7.78 and a beta of 1.55. The business’s fifty day moving average is $4.17 and its 200 day moving average is $2.83. Shattuck Labs has a 12-month low of $0.69 and a 12-month high of $6.00.

Shattuck Labs (NASDAQ:STTK) last released its quarterly earnings results on Thursday, March 5th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.12). The firm had revenue of ($1.00) million for the quarter, compared to the consensus estimate of $0.17 million. On average, analysts expect that Shattuck Labs will post -1.48 EPS for the current year.

Institutional Investors Weigh In On Shattuck Labs

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Y Intercept Hong Kong Ltd bought a new stake in shares of Shattuck Labs during the 2nd quarter valued at $98,000. Aberdeen Group plc boosted its holdings in Shattuck Labs by 462.1% in the 4th quarter. Aberdeen Group plc now owns 531,177 shares of the company’s stock worth $1,939,000 after buying an additional 436,673 shares during the period. Mallini Complete Financial Planning LLC bought a new position in Shattuck Labs in the 4th quarter worth $83,000. Keel Point LLC purchased a new stake in Shattuck Labs in the 3rd quarter worth $110,000. Finally, Virtu Financial LLC purchased a new stake in Shattuck Labs in the 3rd quarter worth $38,000. Institutional investors own 58.74% of the company’s stock.

Shattuck Labs News Summary

Here are the key news stories impacting Shattuck Labs this week:

• Positive Sentiment: Needham initiated coverage with a “Buy” and a $25.00 price target, a materially higher target that signals strong upside and likely attracted buying interest. Needham Initiation
• Positive Sentiment: Wedbush raised its price target from $4.00 to $8.00 and kept an “Outperform” rating, providing additional analyst support and a nearer-term beat-the-street catalyst. Wedbush Target Raise
• Negative Sentiment: HC Wainwright cut its FY2026–FY2028 EPS forecasts (FY2026 to ($0.83) from ($0.71); FY2027 to ($0.88) from ($0.76); FY2028 to ($1.04) from ($0.90)) while still maintaining a “Buy” rating and a $6 price target — the revisions signal slower expected progress in profitability and could pressure longer-term expectations. HC Wainwright Note
• Negative Sentiment: Shattuck’s published Q4/FY2025 results showed EPS roughly in line with estimates but revenue missed expectations (company reported negative/weak revenue for the quarter vs. consensus), a mixed report that limits upside from fundamentals until revenue trends improve. Q4 & FY2025 Results

About Shattuck Labs

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.